Bank of New Hampshire Sells 915 Shares of Pfizer Inc. (NYSE:PFE)

Bank of New Hampshire decreased its position in Pfizer Inc. (NYSE:PFE) by 42.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,266 shares of the biopharmaceutical company’s stock after selling 915 shares during the period. Bank of New Hampshire’s holdings in Pfizer were worth $37,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. LGT Group Foundation boosted its stake in Pfizer by 2.5% during the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock worth $20,786,000 after buying an additional 18,274 shares in the last quarter. ORG Partners LLC boosted its holdings in Pfizer by 1,729.9% during the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after purchasing an additional 44,458 shares in the last quarter. Kempner Capital Management Inc. acquired a new position in shares of Pfizer in the 1st quarter worth approximately $2,439,000. Leo Wealth LLC acquired a new stake in Pfizer in the 4th quarter valued at $2,171,000. Finally, Power Corp of Canada grew its position in Pfizer by 28.1% in the fourth quarter. Power Corp of Canada now owns 174,201 shares of the biopharmaceutical company’s stock valued at $5,015,000 after acquiring an additional 38,243 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE:PFE opened at $29.19 on Tuesday. The stock has a market capitalization of $165.41 billion, a PE ratio of -486.50, a P/E/G ratio of 1.23 and a beta of 0.67. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $33.92. The firm has a fifty day simple moving average of $29.17 and a 200 day simple moving average of $28.32. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter last year, the company posted $0.67 earnings per share. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on PFE. Barclays boosted their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. StockNews.com cut Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Thursday, October 3rd. Nine equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.